XML 19 R6.htm IDEA: XBRL DOCUMENT v3.23.4
Consolidated Statements of Changes in Stockholders’ Equity - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Shareholder’s Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2021 $ 145,979 $ 228,084,195 $ (96,047,821) $ 132,182,353 $ 600,380 $ 132,782,733
Balance (in Shares) at Sep. 30, 2021   145,979,429          
Issuance of common stock for services $ 232 377,972 378,204 378,204
Issuance of common stock for services (in Shares)   231,701          
Stock-based compensation expense 3,905,954 3,905,954 3,905,954
Net loss (33,640,646) (33,640,646) (33,640,646)
Balance at Sep. 30, 2022 $ 146,211 232,368,121 (129,688,467) 102,825,865 600,380 103,426,245
Balance (in Shares) at Sep. 30, 2022   146,211,130          
Issuance of common stock for services $ 100 101,900 102,000 102,000
Issuance of common stock for services (in Shares)   100,000          
Issuance of common stock upon exercise of stock options $ 47 31,220 31,267 $ 31,267
Issuance of common stock upon exercise of stock options (in Shares)   46,667         46,667
Issuance of common stock in registered direct offering, net of costs of $1,201,818 $ 12,500 13,785,683 13,798,183 $ 13,798,183
Issuance of common stock in registered direct offering, net of costs of $1,201,818 (in Shares)   12,500,001          
Stock-based compensation expense 6,616,705 6,616,705 6,616,705
Net loss (32,542,912) (32,542,912) (32,542,912)
Balance at Sep. 30, 2023   $ 158,858 $ 252,903,629 $ (162,231,379) $ 90,831,108 $ 600,380 $ 91,431,488
Balance (in Shares) at Sep. 30, 2023   158,857,798